Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF138.6m

Newron Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Newron Pharmaceuticals has been growing earnings at an average annual rate of 4.4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 10.4% per year.

Key information

4.4%

Earnings growth rate

4.4%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate10.4%
Return on equityn/a
Net Margin-179.1%
Next Earnings Update19 Sep 2024

Recent past performance updates

Recent updates

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06
Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01
Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25
A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Revenue & Expenses Breakdown
Beta

How Newron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SWX:NWRN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 239-16813
30 Sep 239-16813
30 Jun 239-16812
31 Mar 237-17712
31 Dec 226-17712
30 Sep 226-16711
30 Jun 226-14710
31 Mar 226-15710
31 Dec 216-15711
30 Sep 216-17812
30 Jun 215-20814
31 Mar 215-20814
31 Dec 205-21815
30 Sep 206-19915
30 Jun 207-17915
31 Mar 207-181016
31 Dec 197-201017
30 Sep 196-211116
30 Jun 194-211115
31 Mar 194-181012
31 Dec 184-15910
30 Sep 184-1599
30 Jun 184-1499
31 Mar 189-1098
31 Dec 1713-598
30 Sep 1714-5108
30 Jun 1715-5108
31 Mar 1711-101010
31 Dec 167-151012
30 Sep 166-201013
30 Jun 164-25915
31 Mar 163-24913
31 Dec 152-23911
30 Sep 152-1889
30 Jun 152-1286
31 Mar 152-1175
31 Dec 142-1074
30 Sep 142-1074
30 Jun 143-974
31 Mar 143-873
31 Dec 134-772
30 Sep 134-782
30 Jun 134-893
31 Mar 136-593

Quality Earnings: NWRN is currently unprofitable.

Growing Profit Margin: NWRN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NWRN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare NWRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NWRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.4%).


Return on Equity

High ROE: NWRN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.